Skip to main content
SpringerLink
Log in

Advances in the Diagnosis and Treatment of Alzheimer’s Disease

  • Chapter
Frontiers in Biomedicine

  • 69 Accesses

Abstract

In 1985, the Office of Technology Assessment estimated the U.S. census for the next 50 years. It was predicted that in 1990, 12.5% of the U.S. population would be over the age 65. By 2040,22.5% percent of the U.S. population was predicted to be over the age of 65. Most importantly, individuals over the age of 85 were predicted to increase most rapidly, indicating a marked growth in the old-old. All modern industrial societies are undergoing similar population and demographic changes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons. JAMA 1989;262:2551–2556.

    Article  PubMed  CAS  Google Scholar 

  2. Ernst RL, and Hay JW. The U.S. economic and social costs of Alzheimer’s disease revisited. Am J Public Health 1994;84:1261–1264.

    Article  PubMed  CAS  Google Scholar 

  3. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgen Zeit Psychiat Psych-Gerich Med 1907:64:146–148.

    Google Scholar 

  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Washington, D.C., 1994.

    Google Scholar 

  5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;4:939–944.

    Article  Google Scholar 

  6. Galasko D, Hansen L, Katzman R, Wiederholt W, Masliah E, Terry R, Hill LR, Lessin P, Thal LJ: Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch Neurol 1994;51:888–895.

    Article  PubMed  CAS  Google Scholar 

  7. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, Brayne C, Copeland JRM, Dartigues J-F, Kragh-Sorensen P, Lobo A, Martinez-Lage JM, Stijnen T, Hoffman A, and the EURODEM Incidence Research Group and Work Groups. Rates and risk factors for dementia and risk factors for Alzheimer’s disease. Results from EURODEM pooled analyses. Neurology 1999;52:78–84.

    Article  PubMed  CAS  Google Scholar 

  8. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myer RH, Pericak-Vance PA, Risch N, van Duijn CM, for the APOE and Alzheimer Disease Meta Analysis Consortium. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease. A meta-analysis. JAMA 1997;278:1349–1356.

    Article  PubMed  CAS  Google Scholar 

  9. Hardy J. The Alzheimer family of diseases: Many etiologies, one pathogenesis? Proc Natl Acad Sci USA 1997;94:2095–2097.

    Article  PubMed  CAS  Google Scholar 

  10. Cruts M, Van Broeckhoven C. Molecular genetics of Alzheimer’s disease. In The Dementias, John H. Growden and Martin N. Rossor, eds. Boston, MA: Butterworth-Heinemann, 1998, pp 155–170.

    Google Scholar 

  11. Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scot WK, Terwedow HA, Menold MM, Conneally MP, Small GW, Vance JM, Saunders AM, Roses AD, Haines JL. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on Chromosome 12. JAMA 1997;278:1237–1241.

    Article  PubMed  CAS  Google Scholar 

  12. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. TIPS 1991;12:383–388.

    PubMed  CAS  Google Scholar 

  13. Selkoe D.J. Molecular pathology of Alzheimer’s disease: The role of amyloid. In The Dementias, John H. Growden and Martin N. Rossor, eds. Boston, MA: Butterworth-Heinemann, 1998, pp 257–283.

    Google Scholar 

  14. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457–1459.

    Article  PubMed  CAS  Google Scholar 

  15. Knapp MJ, Knopman DS, Solmon PR, et al. A 30-week randomized controlled trial of highdose tacrine in patients with Alzheimer’s disease. JAMA 1994;271:985–991.

    Article  PubMed  CAS  Google Scholar 

  16. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998;50:136–145.

    Article  PubMed  CAS  Google Scholar 

  17. Corey-Bloom J, Thal LJ: Monoamine oxidase inhibitors in Alzheimer’s disease. In: Monoamine Oxidase Inhibitors in Neuroloical Diseases., A. Lieberman, CW Olanow, MBH Youdim, and K Tipton, eds. New York: Chapman and Hall Medical, 1994, pp 279–294.

    Google Scholar 

  18. Behl C, Davis J, Cole GM, et al: Vitamin E protects nerve cells from amyloid B protein toxicity. Biochem Biophys Res Commun 1992;186:944–950.

    Article  PubMed  CAS  Google Scholar 

  19. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 1997;336:1216–1222.

    Article  PubMed  CAS  Google Scholar 

  20. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195–218.

    Article  PubMed  CAS  Google Scholar 

  21. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: A review of 17 epidemiologic studies. Neurologv 1996;47:425–432.

    Article  CAS  Google Scholar 

  22. Rogers J, Kirby LC, Hempelman SR, et al: Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993;43:1609–1611.

    Article  PubMed  CAS  Google Scholar 

  23. Toran-Allerand CD, Miranda RC, Bentham WDL, et al: Estrogen receptors co-localize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1990;89:4668–4672.

    Article  Google Scholar 

  24. Hu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nat Med 1998;4:447–451.

    Article  Google Scholar 

  25. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA 1998;279:688–695.

    Article  PubMed  CAS  Google Scholar 

  26. Shumaker SA, Reboussin BA, Espeland MA, Rapp SR, McBee WL, Dailey M, Bowen D, Terrell T, Jones BN, for the WHIMS Investigators. The Women’s Health Initiative Memory Study (WHIMS): A trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 1998;19:604–621.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. San Diego, La Jolla, CA, VA Medical Center, University of California, San Diego, CA, 92161, USA

    Leon J. Thal

Authors
  1. Leon J. Thal
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA

    Allan L. Goldstein

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Thal, L.J. (2000). Advances in the Diagnosis and Treatment of Alzheimer’s Disease. In: Goldstein, A.L. (eds) Frontiers in Biomedicine. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4217-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4217-9_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6893-9

  • Online ISBN: 978-1-4615-4217-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation